Hengkang Medical (0022 19) is still stable today. Hengkang Medical Group Co., Ltd. (hereinafter referred to as Hengkang Medical), formerly known as Gansu Duyiwei Biopharmaceutical Co., Ltd., was registered on September 30, 20001year. The company's business covers medical services, medicines, daily chemicals and health products, with more than 1000 employees. In March 2008, the company was listed on the small and medium-sized board market in Shenzhen, and the stock code of Shenzhen Stock Exchange was 0022 19.

The main business scope of Hengkang Medical: medical investment management; Drug production, research and development and sales; Sales of daily chemical products and biological products; Seven hospitals under Hengkang Medical provide medical services to patients all over the country. At the same time, relying on the big health industry, the layout of medicine, daily chemicals, health and other industries. The main products are Lamiophlomis rotata capsules, Shenqi Schisandra tablets, Maiping tablets, Qianliantong tablets, potassium chloride and sodium chloride injection, Lamiophlomis rotata toothpaste, Zhen Ji Rana, and other medicines, daily chemical products and health care products.

1, 2001September, Sichuan Hengkang Development Co., Ltd. and Gansu Duyiwei Pharmaceutical Co., Ltd. jointly established Gansu Duyiwei Biopharmaceutical Co., Ltd. In May 2002, the company invested 30 million yuan and designed a brand-new advanced production base in strict accordance with GMP standards. It was built in Wangbadu Yixu Industrial Park, Kang County, Gansu Province and passed the acceptance test. It produces 6 dosage forms, 32 varieties, exclusive varieties and protected varieties of new drugs and traditional Chinese medicines from many countries, with an annual processing capacity of 1.5 million tons. At the same time, the company successfully moved from Lanzhou to Kangxian Duyiwei Bio-industrial Park. The company passed the national GMP certification at one time, and its unique soft capsule was successfully industrialized and obtained the approval for new drug production. The workshop of the company's soft capsule production line successfully passed GMP certification, which laid the foundation for the large-scale production of new products. The company successfully realized the industrialization of Gongliuning Capsule and obtained the approval of new drug production.

2. The company's national Chinese herbal medicine production support project "Duyiwei Tibetan Medicine Artificial Planting" was successful, and invested and built a "Duyiwei" pasture planting base covering an area of 30,000 mu in Maqu County, Gannan, with remarkable results. It is of great significance to protect the wild resources of Lamiophlomis rotata and promote its industrial application. At the same time, the company also applied to People's Republic of China (PRC) and the Ministry of Commerce for an exclusive certificate of origin. The third extraordinary shareholders' meeting was held in Chengdu in 2006. After voting, the company's overall restructuring plan was passed. On February 29th, 65438, the company was officially restructured into Gansu Duyiwei Biopharmaceutical Co., Ltd., and the first board of directors and board of supervisors were formed, and 9 directors and 3 supervisors were elected.

3. The company and the Journal of Continuing Education of Chinese Medical Association jointly held "Medical Research Thinking and Thesis Writing Class" in Chongqing, Dalian, Beijing, Zibo and other places, which greatly improved the popularity of medical research. The company was listed in Shenzhen small and medium-sized board market, becoming the first pharmaceutical listed company in Gansu Province. The company takes medical service as its strategic direction and is fully involved in the medical service industry. The company has made great progress in the field of medical mergers and acquisitions, and has acquired five hospitals. The company changed its name to Hengkang Medical, strengthened the strategic direction of medical care, began to acquire large-scale dimethyl hospitals, and actively participated in the restructuring of public hospitals. On the evening of 2017112, Hengkang Medical announced that the company confirmed the suspension of the non-public offering of shares due to major events. Among them, the investment project of raised funds involves the acquisition of assets in cash, and the acquisition target is the equity of medical service industry company. The estimated transaction amount is about 3 billion yuan.